BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15768590)

  • 1. [Aldosterone antagonist therapy for chronic heart failure].
    Yamamoto T; Yano M
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
    Funder JW
    Am Heart J; 2002 Nov; 144(5 Suppl):S8-11. PubMed ID: 12422135
    [No Abstract]   [Full Text] [Related]  

  • 4. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 5. Aldosterone in heart failure: pathophysiology and treatment.
    Struthers AD
    Curr Heart Fail Rep; 2004 Dec; 1(4):171-5. PubMed ID: 16036041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
    Tatsumi T; Matsubara H
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%.
    Birocchi S; Cernuschi GC;
    Intern Emerg Med; 2011 Oct; 6(5):453-4. PubMed ID: 21769601
    [No Abstract]   [Full Text] [Related]  

  • 13. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Karagiannis A; Athyros VG; Mikhailidis DP
    Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
    [No Abstract]   [Full Text] [Related]  

  • 18. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 20. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.